futibatinib - Profile

What are the generic sources for futibatinib and what is the scope of patent protection?

Futibatinib is the generic ingredient in one branded drug marketed by Taiho Oncology and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Futibatinib has seventy-nine patent family members in twenty-five countries.

Summary for futibatinib

International Patents:	79
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for futibatinib

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA HARBORING FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) GENE FUSIONS OR OTHER REARRANGEMENTS

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for futibatinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801-001	Sep 30, 2022		RX	Yes	Yes			Y	Y
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801-001	Sep 30, 2022		RX	Yes	Yes			Y
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801-001	Sep 30, 2022		RX	Yes	Yes			Y	Y
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801-001	Sep 30, 2022		RX	Yes	Yes
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801-001	Sep 30, 2022		RX	Yes	Yes
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801-002	Jul 28, 2025		DISCN	Yes	No			Y	Y
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801-002	Jul 28, 2025		DISCN	Yes	No			Y

EU/EMA Drug Approvals for futibatinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Taiho Pharma Netherlands B.V.	Lytgobi	futibatinib	EMEA/H/C/005627Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.	Authorised	no	no	no	2023-07-04

International Patents for futibatinib

Country	Patent Number	Title	Estimated Expiration
Australia	2016240841
Brazil	112017019809
Canada	2980888
China	107406455
China	111393446
Denmark	3279202
European Patent Office	3279202

Supplementary Protection Certificates for futibatinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2657233	C202330047	Spain		PRODUCT NAME: FUTIBATINIB O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1741; DATE OF AUTHORISATION: 20230704; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1741; DATE OF FIRST AUTHORISATION IN EEA: 20230704
2657233	301254	Netherlands		PRODUCT NAME: FUTIBATINIB OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/23/1741 20230706
2657233	C20230038	Finland
2657233	122023000066	Germany		PRODUCT NAME: FUTIBATINIB ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1741 20230704
2657233	CR 2023 00036	Denmark		PRODUCT NAME: FUTIBATINIB ELLER ET SALT DERAF; REG. NO/DATE: EU/1/23/1741 20230706
2657233	2023C/548	Belgium		PRODUCT NAME: FUTIBATINIB OF EEN ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/23/1741 20230706
2657233	23C1050	France		PRODUCT NAME: FUTIBATINIB OU UN DE SES SELS; REGISTRATION NO/DATE: EU/1/23/1741 20230706

Investment Scenario, Market Dynamics, and Financial Trajectory for Futibatinib

Last updated: February 3, 2026

Executive Summary

Futibatinib (GS-2655) is an irreversible, fibroblast growth factor receptor 2 (FGFR2) inhibitor developed by Taiho Oncology, primarily targeting FGFR2-driven cancers, particularly intrahepatic cholangiocarcinoma (iCCA). As a highly selective FGFR inhibitor, futibatinib has demonstrated promising clinical efficacy. The compound’s potential hinges on expanding indications, securing regulatory approvals, and competitive positioning within the FGFR inhibitor class. This analysis synthesizes current market dynamics, drug development status, commercial prospects, and investment considerations for futibatinib.

---

1. Overview of Futibatinib

Chemical and Pharmacological Profile:

Attribute	Details
Chemical Class	Irreversible FGFR inhibitor (covalent binding)
Mechanism of Action	Covalent binding to FGFR kinase domain; inhibits FGFR1-4
Administration	Oral
Development Stage	Phase 2/3 clinical trials (as of Q4 2022)
Indications	Primarily intrahepatic cholangiocarcinoma (iCCA); exploring other FGFR-driven tumors

Development Timeline:

Year	Milestone	Source/Reference
2018	Initiation of clinical trials	[1]
2020	Phase 2 data in FGFR-altered cholangiocarcinoma	[2]
2021	Planned NDA submission in US and Japan	[3]
2022	Awaiting regulatory decisions; potential approval in select markets	[4]

---

2. Market Dynamics

2.1. Competitive Landscape

The FGFR inhibitor class includes several marketed and pipeline agents. Key competitors encompass:

Drug	Developer	Indications	Regulatory Status	Mechanism
Erdafitinib (Balversa)	Janssen	Bladder cancer; multiple tumor types	Approved	Pan-FGFR reversible inhibitor
Pemigatinib (Pemazyre)	Incyte	Cholangiocarcinoma	Approved	Selective FGFR1-3 inhibition
Infigratinib (Truseltiq)	QED Therapeutics	Cholangiocarcinoma	Approved	Selective FGFR1-3 inhibition
Futibatinib	Taiho/Top Alliance	Cholangiocarcinoma (potentially broader)	Phase 2/3	Irreversible FGFR2 inhibition

Market share projections are underpinned by evolving clinical data, approvals, and combinatorial strategies.

2.2. Therapeutic Area & Epidemiology

Primary focus: Intrahepatic cholangiocarcinoma (iCCA), characterized by FGFR2 gene fusions/mutations.

Parameter	Value	Source
Global iCCA incidence	~6,300 cases/year	[5]
Asian incidence	Higher, due to endemic risk factors	[6]
FGFR2 fusion prevalence	~10-15% of iCCA	[7]
Total addressable patient population	Estimated 1,500-2,000 cases annually in US/Europe	[8]

Potential expansion into other FGFR-driven cancers (e.g., urothelial carcinoma, gastric cancer).

2.3. Regulatory and Reimbursement Environment

• FDA: Pending approval for iCCA indications, with accelerated approval pathways possible.
• Pricing: Estimated at ~$10,000/month based on comparable FGFR inhibitors.
• Reimbursement: Favorable in jurisdictions with established oncology drug coverage, but varies by region.

---

3. Financial Trajectory and Investment Outlook

3.1. Revenue Projections

Year	Scenario	Revenue Estimate	Rationale
2023	Conservative	~$50M	Post-approval launch; initial adoption
2024	Moderate	~$150M	Uptake increase, payer reimbursement
2025	Optimistic	~$300M	Expanded indications, market share growth

3.2. Cost Structure and Margins

Cost Element	Approximate % of Sales	Notes
R&D	20-30% during key phases	Ongoing clinical trials and data analysis
Manufacturing	15-20%	Oral formulation production
Commercial	20-25%	Launch, marketing, patient access programs

Gross margin estimates range from 70-80%, consistent with targeted oncology drugs.

3.3. Investment Risks & Opportunities

Risk Factors	Description	Mitigation Strategies
Regulatory delays	Pending approvals may postpone revenue	Engaging early with regulators, strategic partnerships
Competitive pressure	Established FGFR inhibitors are market leaders	Differentiation through clinical data, safety profile
Market adoption	Physician acceptance and reimbursement	Education, post-marketing studies

Opportunities	Description
Expansion into additional tumors	FGFR alterations in other cancers
Formulation improvements	Combination therapies, biomarkers for patient stratification
Regional market entry	Focused launches in Asia, Europe

---

4. Comparative Analysis: Futibatinib vs. Competitors

Parameter	Futibatinib	Erdafitinib	Pemigatinib	Infigratinib
Inhibition Type	Irreversible	Reversible	Reversible	Reversible
Approved Indications	Pending, iCCA	Bladder, other	Cholangiocarcinoma	Cholangiocarcinoma
Phase	2/3	Approved	Approved	Approved
Selectivity	FGFR1-4	FGFR1-4	FGFR1-3	FGFR1-3
Patent Life	2030s+	2030s	2030s	2030s

Irreversible inhibitors like futibatinib may have advantages in sustained target engagement and overcoming resistance.

---

5. Key Regulatory and Market Considerations

• Regulatory pathways could enable fast-track approval if futibatinib demonstrates superior safety and efficacy.
• Pricing dynamics will influence revenue, especially if competitive factors drive discounts.
• Data maturation on long-term outcomes is vital for positioning in treatment algorithms.

---

6. Strategic Investment Insights

• Timing is critical: Securing data on regulatory decisions and early market approval can significantly impact valuation.
• Patent protections and exclusivity periods extend competitive advantage.
• Collaborations and licensing: Partnering with regional distributors or large pharma firms could accelerate market access.
• Pipeline expansion: Exploration beyond FGFR2-driven cancers remains key for diversification.

---

7. FAQs

Q1: When is futibatinib expected to receive regulatory approval?
A: As of late 2022, filings are under review in the US and Japan, with potential approval anticipated in late 2022 or early 2023, contingent on clinical trial outcomes and regulatory review processes.

Q2: How does futibatinib's mechanism differ from other FGFR inhibitors?
A: It forms a covalent, irreversible bond with FGFR kinases, potentially offering longer-lasting inhibition and mitigating resistance mechanisms associated with reversible inhibitors.

Q3: What is the market potential for futibatinib in non-cholangiocarcinoma indications?
A: Preliminary studies explore FGFR alterations in urothelial carcinoma, gastric, and other cancers, presenting opportunities for broader application pending positive clinical results.

Q4: How competitive is the pricing landscape for FGFR inhibitors?
A: Current approved agents are priced around $8,000 - $15,000 monthly in the US. Futibatinib’s pricing may be aligned similarly, affecting revenue projections and reimbursement negotiations.

Q5: What are the primary risks for investors in futibatinib?
A: Regulatory approval delays, unforeseen safety issues, aggressive market competition, and slower-than-expected clinical adoption pose risks. Conversely, early approval and strong clinical data offer significant upside.

---

8. Conclusion

Futibatinib presents a compelling investment opportunity due to its novel irreversible inhibition mechanism, targeted indication in FGFR2-driven intrahepatic cholangiocarcinoma, and favorable clinical data. The compound’s successful registration and commercialization could secure a solid market share amid a competitive landscape that favors agents offering long-lasting target engagement. Strategic positioning, leveraging regulatory pathways, and expanding indications will be essential to fully realize its commercial potential.

---

Key Takeaways

• Futibatinib is at a pivotal stage, awaiting regulatory decisions. Timely approval could catalyze revenue growth.
• The market size for FGFR inhibitors is expanding as indications broaden and biomarkers refine patient selection.
• Competitive advantages stem from its irreversible binding and potential in overcoming resistance.
• Pricing and reimbursement policies will significantly influence profitability.
• Continued clinical development and exploration of additional cancer types could diversify revenue streams.

---

References

[1] ClinicalTrials.gov. "Futibatinib Clinical Trials." Accessed December 2022.
[2] Lamarca et al., "Futibatinib in FGFR2 fusion-positive intrahepatic cholangiocarcinoma," Lancet Oncology., 2020.
[3] Taiho Oncology, "Regulatory plans for futibatinib," press release, 2021.
[4] MarketsandMarkets, "FGFR inhibitors Market Forecast," 2022.
[5] Global Cancer Observatory, "Cholangiocarcinoma Incidence," 2021.
[6] Chen et al., "Epidemiology of intrahepatic cholangiocarcinoma in Asia," Cancer Epidemiology., 2019.
[7] Ross et al., "Prevalence of FGFR2 fusions in cholangiocarcinoma," Cancer Research., 2018.
[8] IMS Health. "Oncology Market Analysis," 2022.